Sandra Regina Loggetto
Research Subjects
Sandra Regina Loggetto has a total of 91 co-authors. Here are the top co-authors by number of shared publications:
- Josefina Aparecida Pellegrini Braga
Universidade Federal de São Paulo
4 shared publications Mônica Pinheiro de Almeida Veríssimo
Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular (ABHH), São Paulo, SP, Brazil; Centro Infantil de Investigações Hematológicas Dr. Domingos A. Boldrini, Campinas, SP, Brazil
3 shared publicationsAderson da Silva Araujo
Fundacao Hematol & Hemoterapia Pernambuco HEMOPE, Recife, PE, Brazil
2 shared publicationsAntonio Fabron Junior
Hemoctr Marilia, Marilia, SP, Brazil
2 shared publications- Eduardo Cerello Chapchap
Hospital Israelita Albert Einstein, São Paulo, SP, Brazil
2 shared publications Fernando Tricta
ApoPharma, Med Affairs, Toronto, ON, Canada
2 shared publications
Latest Publications
- Open Access
- 2 May 2026
- Published by Elsevier in Hematology, Transfusion and Cell Therapy
- Vol. 48 (3) , 106461
Socio-demographic and therapeutic profile of people living with thalassemia in Brazil between 2012 and 2022: A cross-sectional study
- 2 May 2026
- Published by Elsevier in Hematology, Transfusion and Cell Therapy
- Vol. 48 (3) , 106461
Open AccessSocio-demographic and therapeutic profile of people living with thalassemia in Brazil between 2012 and 2022: A cross-sectional study
- Open Access
- 24 April 2026
- Published by Elsevier in Hematology, Transfusion and Cell Therapy
- Vol. 48 (2) , 106456
Criteria for referring pediatric and adult patients with hematological diseases to palliative care: Consensus of the Brazilian Association of Hematology, hemotherapy and cell therapy (2025)
- 24 April 2026
- Published by Elsevier in Hematology, Transfusion and Cell Therapy
- Vol. 48 (2) , 106456
Open AccessCriteria for referring pediatric and adult patients with hematological diseases to palliative care: Consensus of the Brazilian Association of Hematology, hemotherapy and cell therapy (2025)
- Open Access
- 26 August 2023
- Published by Elsevier in Hematology, Transfusion and Cell Therapy
- Vol. 46 (Suppl 5) , S143-S151
Extramedullary haematopoiesis in patients with thalassemia: a cross-sectional description of its prevalence, clinical features and survival
- 26 August 2023
- Published by Elsevier in Hematology, Transfusion and Cell Therapy
- Vol. 46 (Suppl 5) , S143-S151
Open AccessExtramedullary haematopoiesis in patients with thalassemia: a cross-sectional description of its prevalence, clinical features and survival
- Open Access
- 6 April 2023
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 18 (4) , e0282423
The impact of COVID-19 in children with Sickle Cell Disease: Results of a multicentric registry
To analyze the outcomes of children with sickle cell disease (SCD) and COVID-19. A multicenter prospective study was conducted in five hematological centers from Central and Southeast Brazil, starting in April 2020. The variables recorded include clinical symptoms, diagnostic methods, therapeutic measures, and treatment sites. The clinical repercussions of the infection on the initial treatment and the overall prognosis were also evaluated. Twenty-five unvaccinated children, aged 4 to 17 years, with SCD and a positive SARS-CoV-2 RT-PCR result participated in this study. Patients were classified as SCD types SS (n = 20, 80%) and SC (n = 5, 20%). Clinical characteristics and evolution were similar in both groups (p>0.05), except for the fetal hemoglobin value which was higher among the SC patients (p = 0.025). The most frequent symptoms were hyperthermia (72%) and cough (40%). Three children were admitted to the intensive care unit, all of whom were overweight/obese (p = 0.078). No deaths were observed. Although SCD leads to specific complications, the results found in this sample suggest that COVID-19 does not seem to carry an increased mortality risk in pediatric patients with this disease.
- 6 April 2023
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 18 (4) , e0282423
Open AccessThe impact of COVID-19 in children with Sickle Cell Disease: Results of a multicentric registry
To analyze the outcomes of children with sickle cell disease (SCD) and COVID-19. A multicenter prospective study was conducted in five hematological centers from Central and Southeast Brazil, starting in April 2020. The variables recorded include clinical symptoms, diagnostic methods, therapeutic measures, and treatment sites. The clinical repercussions of the infection on the initial treatment and the overall prognosis were also evaluated. Twenty-five unvaccinated children, aged 4 to 17 years, with SCD and a positive SARS-CoV-2 RT-PCR result participated in this study. Patients were classified as SCD types SS (n = 20, 80%) and SC (n = 5, 20%). Clinical characteristics and evolution were similar in both groups (p>0.05), except for the fetal hemoglobin value which was higher among the SC patients (p = 0.025). The most frequent symptoms were hyperthermia (72%) and cough (40%). Three children were admitted to the intensive care unit, all of whom were overweight/obese (p = 0.078). No deaths were observed. Although SCD leads to specific complications, the results found in this sample suggest that COVID-19 does not seem to carry an increased mortality risk in pediatric patients with this disease.
- Open Access
- 1 January 2023
- Published by Elsevier in Hematology, Transfusion and Cell Therapy
- Vol. 45 (1) , 7-15
Cardiac iron overload evaluation in thalassaemic patients using T2* magnetic resonance imaging following chelation therapy: a multicentre cross-sectional study
- 1 January 2023
- Published by Elsevier in Hematology, Transfusion and Cell Therapy
- Vol. 45 (1) , 7-15
Open AccessCardiac iron overload evaluation in thalassaemic patients using T2* magnetic resonance imaging following chelation therapy: a multicentre cross-sectional study
- Open Access
- 20 April 2022
- Published by Jornal Brasileiro de Economia da Saude in Jornal Brasileiro de Economia da Saúde
- Vol. 14 (1) , 41-50
Blinatumomabe em pacientes pediátricos com leucemia linfoblástica aguda B em primeira recidiva de alto risco: um estudo de custo-efetividade
Objetivo: Estimar a custo-efetividade do blinatumomabe como novo padrão no tratamento de consolidação de pacientes pediátricos com leucemia linfoblástica aguda de células precursoras B (LLA-B) em primeira recidiva de alto risco. Métodos: Um modelo de sobrevida particionado com horizonte lifetime e ciclo de quatro semanas foi construído na perspectiva do Sistema Único de Saúde (SUS). Sobrevida livre de eventos e sobrevida global foram extrapoladas com base no ensaio clínico 20120215, usando funções paramétricas. A taxa de desconto foi de 5%. O impacto de variações em pressupostos foi explorado em análises de cenário. Resultados: O custo lifetime com desconto para o caso base foi de R$ 351.615 para blinatumomabe contra R$ 97.770 para HC3 (grupo controle de quimioterapia-padrão), com ganho de 9,96 e 6,74 anos de vida ajustados para qualidade (QALYs), respectivamente. A razão de custo-efetividade incremental (RCEI) foi de R$ 78.873/QALY. Considerando um cenário sem descontos, a RCEI foi de R$ 33.731/QALY ganho. Os outros cenários com maior impacto na RCEI foram a exclusão do desperdício de blinatumomabe (isto é, considerando que a sobra em frasco-ampola de um paciente seria reaproveitada para outro paciente: R$ 35.751) e a alteração do tempo de infusão (troca de bolsa em 48 ou 96 horas em vez de 24 horas: R$ 35.515). A probabilidade de o blinatumomabe ser custo-efetivo foi de 65,7% na análise probabilística, considerando um limiar de R$ 95.501. Conclusões: Blinatumomabe é custo-efetivo para pacientes pediátricos com LLA-B derivada em primeira recidiva de alto risco na perspectiva do SUS.
- 20 April 2022
- Published by Jornal Brasileiro de Economia da Saude in Jornal Brasileiro de Economia da Saúde
- Vol. 14 (1) , 41-50
Open AccessBlinatumomabe em pacientes pediátricos com leucemia linfoblástica aguda B em primeira recidiva de alto risco: um estudo de custo-efetividade
Objetivo: Estimar a custo-efetividade do blinatumomabe como novo padrão no tratamento de consolidação de pacientes pediátricos com leucemia linfoblástica aguda de células precursoras B (LLA-B) em primeira recidiva de alto risco. Métodos: Um modelo de sobrevida particionado com horizonte lifetime e ciclo de quatro semanas foi construído na perspectiva do Sistema Único de Saúde (SUS). Sobrevida livre de eventos e sobrevida global foram extrapoladas com base no ensaio clínico 20120215, usando funções paramétricas. A taxa de desconto foi de 5%. O impacto de variações em pressupostos foi explorado em análises de cenário. Resultados: O custo lifetime com desconto para o caso base foi de R$ 351.615 para blinatumomabe contra R$ 97.770 para HC3 (grupo controle de quimioterapia-padrão), com ganho de 9,96 e 6,74 anos de vida ajustados para qualidade (QALYs), respectivamente. A razão de custo-efetividade incremental (RCEI) foi de R$ 78.873/QALY. Considerando um cenário sem descontos, a RCEI foi de R$ 33.731/QALY ganho. Os outros cenários com maior impacto na RCEI foram a exclusão do desperdício de blinatumomabe (isto é, considerando que a sobra em frasco-ampola de um paciente seria reaproveitada para outro paciente: R$ 35.751) e a alteração do tempo de infusão (troca de bolsa em 48 ou 96 horas em vez de 24 horas: R$ 35.515). A probabilidade de o blinatumomabe ser custo-efetivo foi de 65,7% na análise probabilística, considerando um limiar de R$ 95.501. Conclusões: Blinatumomabe é custo-efetivo para pacientes pediátricos com LLA-B derivada em primeira recidiva de alto risco na perspectiva do SUS.
- Open Access
- 25 February 2022
- Published by Elsevier in Hematology, Transfusion and Cell Therapy
- Vol. 44 (2) , 246-255
Guidelines on sickle cell disease: secondary stroke prevention in children and adolescents. Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular guidelines project: Associação Médica Brasileira - 2022
- 25 February 2022
- Published by Elsevier in Hematology, Transfusion and Cell Therapy
- Vol. 44 (2) , 246-255
Open AccessGuidelines on sickle cell disease: secondary stroke prevention in children and adolescents. Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular guidelines project: Associação Médica Brasileira - 2022
- Open Access
- 16 November 2021
- Published by Elsevier in Hematology, Transfusion and Cell Therapy
- Vol. 44 (1) , 85-94
Guidelines on sickle cell disease: primary stroke prevention in children and adolescents. Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Guidelines project: Associação Médica Brasileira - 2021
- 16 November 2021
- Published by Elsevier in Hematology, Transfusion and Cell Therapy
- Vol. 44 (1) , 85-94
Open AccessGuidelines on sickle cell disease: primary stroke prevention in children and adolescents. Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Guidelines project: Associação Médica Brasileira - 2021
- Open Access
- 16 November 2019
- Published by Elsevier in The Brazilian Journal of Infectious Diseases
- Vol. 23 (6) , 395-409
A consensus document for the clinical management of invasive fungal diseases in pediatric patients with hematologic cancer and/or undergoing hematopoietic stem cell transplantation in Brazilian medical centers
- 16 November 2019
- Published by Elsevier in The Brazilian Journal of Infectious Diseases
- Vol. 23 (6) , 395-409
Open AccessA consensus document for the clinical management of invasive fungal diseases in pediatric patients with hematologic cancer and/or undergoing hematopoietic stem cell transplantation in Brazilian medical centers
- Open Access
- 8 April 2016
- Published by Elsevier in Revista Brasileira de Ginecologia e Obstetrícia
- Vol. 38 (2) , 147-157
Guidelines on neonatal screening and painful vaso-occlusive crisis in sickle cell disease: Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular
- 8 April 2016
- Published by Elsevier in Revista Brasileira de Ginecologia e Obstetrícia
- Vol. 38 (2) , 147-157
Open AccessGuidelines on neonatal screening and painful vaso-occlusive crisis in sickle cell disease: Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular